NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019
NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019
SUMMARY
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) pipeline Target constitutes close to 10 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019, outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - NAD-dependent deacetylase sirtuin-1 is a protein encoded by the SIRT1 gene. It modulates chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. It is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). The molecules developed by companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Hematological Disorders, Infectious Disease and Respiratory which include indications Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Obesity, Type 2 Diabetes, Bacterial Pneumonia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Ewing Sarcoma, Fanconi Anemia, Hyperlipidemia, Peritonitis, Solid Tumor and Traumatic Nerve Injury.
Furthermore, this report also reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) pipeline Target constitutes close to 10 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019, outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - NAD-dependent deacetylase sirtuin-1 is a protein encoded by the SIRT1 gene. It modulates chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. It is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). The molecules developed by companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Hematological Disorders, Infectious Disease and Respiratory which include indications Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Obesity, Type 2 Diabetes, Bacterial Pneumonia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Ewing Sarcoma, Fanconi Anemia, Hyperlipidemia, Peritonitis, Solid Tumor and Traumatic Nerve Injury.
Furthermore, this report also reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
- The report reviews NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics and enlists all their major and minor projects
- The report assesses NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Overview
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Jyant Technologies Inc
NuSirt Biopharma Inc
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Drug Profiles
(acamprosate + ribavirin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + metformin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resveratrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resveratrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-3025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoflavin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Dormant Products
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Discontinued Products
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Product Development Milestones
Featured News & Press Releases
Jun 10, 2016: NuSirt Biopharma Presenting New Research at American Diabetes Association's 76th Annual Scientific Sessions
Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions
May 18, 2016: NuSirt Biopharma to Present at American Diabetes Association's 76th Scientific Sessions
Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
Jun 25, 2015: New Study: NuSirt Technology Demonstrates Potential as New Type 2 Diabetes Therapy
Jun 06, 2015: NuSirt Biopharma Presenting New Data On Leucine-Metformin Combination at American Diabetes Association 75th Scientific Sessions
Jul 18, 2014: Nashville-based pharmaceutical company readies for human trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Overview
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Jyant Technologies Inc
NuSirt Biopharma Inc
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Drug Profiles
(acamprosate + ribavirin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + metformin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resveratrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resveratrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-3025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoflavin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Dormant Products
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Discontinued Products
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Product Development Milestones
Featured News & Press Releases
Jun 10, 2016: NuSirt Biopharma Presenting New Research at American Diabetes Association's 76th Annual Scientific Sessions
Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions
May 18, 2016: NuSirt Biopharma to Present at American Diabetes Association's 76th Scientific Sessions
Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
Jun 25, 2015: New Study: NuSirt Technology Demonstrates Potential as New Type 2 Diabetes Therapy
Jun 06, 2015: NuSirt Biopharma Presenting New Data On Leucine-Metformin Combination at American Diabetes Association 75th Scientific Sessions
Jul 18, 2014: Nashville-based pharmaceutical company readies for human trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Jyant Technologies Inc, H2 2019
Pipeline by NuSirt Biopharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Jyant Technologies Inc, H2 2019
Pipeline by NuSirt Biopharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
COMPANIES MENTIONED
GlaxoSmithKline Plc
Jyant Technologies Inc
NuSirt Biopharma Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
COMPANIES MENTIONED
GlaxoSmithKline Plc
Jyant Technologies Inc
NuSirt Biopharma Inc
